Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC

NCT03256136 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Carboplatin
DRUG: Nivolumab
DRUG: pemetrexed
DRUG: Ipilimumab

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]